XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 11 - Commitments and Contingencies (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 13, 2022
Oct. 28, 2021
Jun. 15, 2021
Mar. 26, 2020
Mar. 31, 2024
Nov. 30, 2023
Oct. 31, 2023
Jul. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Mar. 14, 2023
Mar. 27, 2020
Research and Development Expense, Total                 $ 2,970 $ 1,125 $ 3,621 $ 1,660      
Payments to Acquire Intangible Assets                     1,868 $ (0)      
Indemnification Rights and Agreements [Member]                              
Other Commitment, Total                 $ 0   0   $ 0    
Common Stock [Member]                              
Share Price (in dollars per share)       $ 3.33                      
Carglumic Acid Tablets [Member]                              
Payments to Acquire Marketing Rights   $ 3,250                          
Commitment, Allocation of Profits, Percentage   50.00%                          
Betaine Anhydrous [Member]                              
Payments to Acquire Marketing Rights $ 2,000         $ 125                  
Commitment, Allocation of Profits, Percentage 65.00%                            
Betaine Anhydrous [Member] | Obligation Based on Commercial Success [Member]                              
Other Commitment, Total $ 1,000                            
FDA-Approved ANDA For Nitisinone [Member]                              
Payments to Acquire Marketing Rights             $ 150                
Commitment, Allocation of Profits, Percentage             80.00%                
FDA-Approved ANDA For Nitisinone [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member]                              
Payments to Acquire Marketing Rights             $ 500                
PKU GoLike [Member]                              
Other Commitment, Total         $ 2,000                    
Royalty on Net Sales of Products, Percent         30.00%                    
Payments to Acquire Marketing Rights         $ 2,350                    
PKU GoLike [Member] | Licensing Agreements [Member]                              
Payments to Acquire Intangible Assets         1,868                    
PKU GoLike [Member] | Inventories [Member]                              
Payments to Acquire Marketing Rights         $ 482                    
Azurity Pharmaceuticals, Inc. (“Azurity”) [Member]                              
Revenue, Additional Based on Event and Sales-based Milestones Achievements               $ 5,500              
Azurity Pharmaceuticals, Inc. (“Azurity”) [Member] | Milestone Method [Member]                              
Revenues                     $ 27,500        
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member]                              
Aggregate Value of Licensing Milestone Included in Research and Development Expense                         $ 1,000    
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Obligation Based on Exclusivity Status from FDA [Member]                              
Other Commitment, Total                             $ 2,500
Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Common Stock [Member]                              
Stock Issued During Period, Shares, New Issues (in shares)       379,474                      
Stock Issued During Period, Value, New Issues       $ 1,264                      
Diurnal Limited [Member] | License [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member]                              
Commitment, Milestone Fee       $ 3,500                      
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member]                              
Research and Development Expense, Total     $ 500                        
Royalty on Net Sales of Products, Percent     10.00%                        
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Development Milestones [Member]                              
Other Commitment, Total     $ 3,500                        
Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Commercial Success [Member]                              
Other Commitment, Total     $ 6,000                        
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Successful Manufacturing of Registration Batches [Member]                              
Other Commitment, Total                           $ 450  
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member]                              
Other Commitment, Total                           $ 200  
Royalties, Percentage of Net Sales,                           12.50%  
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on First Commercial Sale of Product [Member]                              
Other Commitment, Total                           $ 250  
Royalties, Percentage of Net Sales,                           17.00%